AU2021291684A1 - Combination of alcaftadine and a corticosteroid - Google Patents

Combination of alcaftadine and a corticosteroid Download PDF

Info

Publication number
AU2021291684A1
AU2021291684A1 AU2021291684A AU2021291684A AU2021291684A1 AU 2021291684 A1 AU2021291684 A1 AU 2021291684A1 AU 2021291684 A AU2021291684 A AU 2021291684A AU 2021291684 A AU2021291684 A AU 2021291684A AU 2021291684 A1 AU2021291684 A1 AU 2021291684A1
Authority
AU
Australia
Prior art keywords
composition
alcaftadine
corticosteroid
fluticasone
topical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021291684A
Other languages
English (en)
Inventor
Amol AIWALE
Babasaheb Aware
Ulhas Dhuppad
Viraj SHAH
Akhilesh Sharma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alkem Laboratories Ltd
Original Assignee
Alkem Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkem Laboratories Ltd filed Critical Alkem Laboratories Ltd
Publication of AU2021291684A1 publication Critical patent/AU2021291684A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2021291684A 2020-06-15 2021-06-14 Combination of alcaftadine and a corticosteroid Pending AU2021291684A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201921053286 2020-06-15
IN201921053286 2020-06-15
PCT/IB2021/055222 WO2021255622A1 (en) 2020-06-15 2021-06-14 Combination of alcaftadine and a corticosteroid

Publications (1)

Publication Number Publication Date
AU2021291684A1 true AU2021291684A1 (en) 2022-12-08

Family

ID=76523259

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021291684A Pending AU2021291684A1 (en) 2020-06-15 2021-06-14 Combination of alcaftadine and a corticosteroid

Country Status (12)

Country Link
US (1) US20230218630A1 (enExample)
EP (1) EP4164614A1 (enExample)
JP (1) JP7791119B2 (enExample)
KR (1) KR20230024928A (enExample)
CN (1) CN115701988A (enExample)
AU (1) AU2021291684A1 (enExample)
BR (1) BR112022024840A2 (enExample)
CA (1) CA3181959A1 (enExample)
CL (1) CL2022003534A1 (enExample)
MX (1) MX2022015965A (enExample)
WO (1) WO2021255622A1 (enExample)
ZA (1) ZA202212128B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8580801B2 (en) 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
US10598672B2 (en) 2014-02-18 2020-03-24 Cyrano Therapeutics, Inc. Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
WO2021194893A1 (en) 2020-03-24 2021-09-30 Cyrano Therapeutics, Inc. Treatment of chemosensory dysfunction from a coronavirus infection
US20240173331A1 (en) 2021-04-01 2024-05-30 Alkem Laboratories Limited Nasal compositions comprising alcaftadine
WO2023133460A1 (en) * 2022-01-06 2023-07-13 Cyrano Therapeutics, Inc. Improved nasal administration of pharmaceutical formulations
WO2024228988A2 (en) * 2023-05-02 2024-11-07 Cyrano Therapeutics, Inc. Treatment for taste and smell loss
GR1010821B (el) * 2023-11-09 2024-11-15 Ελπεν Α.Ε. Φαρμακευτικη Βιομηχανια, Σταθερο ομογενοποιημενο φαρμακευτικο ρινικο εναιωρημα συνδυασμου αζελαστινης και φλουτικαζονης

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2053678T3 (es) 1987-11-13 1994-08-01 Asta Medica Ag Procedimiento para preparar un medicamento con contenido de azelastina para la aplicacion nasal y/u ocular.
IL101850A (en) 1991-06-13 1996-01-31 Janssen Pharmaceutica Nv 11-(4-Piperidinyl)-imidazo (2,1-b) (3) benzazepine derivatives their preparation and pharmaceutical compositions containing them
DE19947234A1 (de) * 1999-09-30 2001-04-05 Asta Medica Ag Neue Kombination von Loteprednol und Antihistaminika
ES2258175T3 (es) * 2001-12-05 2006-08-16 Alcon, Inc. Utilizacion de un antagonista de h1 y remixolona como esteroide inofensivo para el tratamiento de la rinitis.
BRPI0615032A2 (pt) 2005-09-01 2011-04-26 Biolipox Ab composição farmacêutica, processo para a preparação da mesma, e, uso de uma composição
JP5292277B2 (ja) 2006-03-31 2013-09-18 ビスタコン・フアーマシユーチカルズ・エルエルシー 眼アレルギーの処置
US8569273B2 (en) * 2009-03-17 2013-10-29 Aciex Therapeutics, Inc. Ophthalmic formulations of cetirizine and methods of use
WO2011141929A2 (en) * 2010-05-11 2011-11-17 Cadila Healthcare Limited Aqueous pharmaceutical compositions of fluticasone and olopatadine
CN102283849A (zh) 2011-06-29 2011-12-21 北京阜康仁生物制药科技有限公司 一种含有阿卡他定的药物组合物
JP6294893B2 (ja) * 2012-12-17 2018-03-14 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ 炎症性及び／又はアレルギー性の状態を治療するためのレボカバスチンとフルチカゾンフランカルボン酸エステルとの併用
MY191380A (en) * 2013-09-13 2022-06-21 Glenmark Specialty Sa Stabilized fixed dose drug composition having mometasone and olopatadine
JP7191022B2 (ja) 2017-07-28 2022-12-16 参天製薬株式会社 アルカフタジン又はその塩を含有する水性医薬組成物

Also Published As

Publication number Publication date
CA3181959A1 (en) 2021-12-23
JP7791119B2 (ja) 2025-12-23
MX2022015965A (es) 2023-03-14
JP2023530166A (ja) 2023-07-13
US20230218630A1 (en) 2023-07-13
KR20230024928A (ko) 2023-02-21
EP4164614A1 (en) 2023-04-19
CN115701988A (zh) 2023-02-14
WO2021255622A1 (en) 2021-12-23
BR112022024840A2 (pt) 2022-12-27
ZA202212128B (en) 2024-04-24
CL2022003534A1 (es) 2023-06-23

Similar Documents

Publication Publication Date Title
JP7791119B2 (ja) アルカフタジンとコルチコステロイドの組み合わせ
EP2522365B1 (en) Compositions comprising azelastine and methods of use thereof
US12274702B2 (en) Nasal compositions comprising alcaftadine
EP2736491A2 (en) Bepotastine compositions
JP2009544665A (ja) 炎症病態またはアレルギー病態を治療するための、アゼラスチンとコルチコステロイドとを含む医薬製剤
US20120022032A1 (en) Corticosteroid compositions and methods of treatments thereof
US20260069601A1 (en) Pharmaceutical composition for inhalation for preventing or treating respiratory disease
BRPI0313611B1 (pt) Composição farmacêutica para o tratamento de rinite alérgica e/ou conjuntivite alérgica para aplicação na mucosa e uso de dita composição
RU2582218C2 (ru) Способ получения дозирующего распыляющего ингалятора для лечения респираторного заболевания
EP2739264A1 (en) Pharmaceutical composition comprising ebastine and fluticasone
RU2854644C1 (ru) Композиции для интраназального применения, содержащие алкафтадин
JP7391026B2 (ja) モメタゾン及びオロパタジンの組み合わせを用いた小児対象におけるアレルギー性鼻炎の治療
WO2006097458A1 (en) Novel combination
WO2015009776A1 (en) Low dose corticosteroid microemulsion compositions and methods of treatments thereof
RU2687551C2 (ru) Стабильная фармацевтическая композиция с фиксированной дозой, содержащая мометазон и олопатадин
TW202211919A (zh) 蕈毒鹼性促效劑眼用製劑及其用途
NZ620005B2 (en) Pharmaceutical composition comprising ebastine and fluticasone